Core Viewpoint - The article highlights the diversification and expansion of the fund manager talent pool in the investment industry, with a notable increase in the number of new fund managers since 2026, reflecting the growth and innovation within the fund management sector [1][7]. Group 1: New Fund Managers - As of March 5, 2026, over 100 new fund managers have been appointed, indicating a robust influx of talent into the industry [7]. - Among the new appointees, many possess high educational qualifications, with 99 out of 102 having master's degrees or higher, including 9 PhDs [7]. - The trend shows a shift towards younger fund managers, with 50.9% of the current fund manager cohort being born in the 1980s and 1990s [10]. Group 2: Individual Case Study - Jia Zhi - Jia Zhi has been appointed as a new fund manager at Green Fund, bringing 23 years of experience in the securities industry, including roles at various securities firms and investment advisory companies [2][3]. - His investment style focuses on industry rotation, selective stock picking, and deep research, aiming to achieve returns that exceed performance benchmarks [4][6]. - Jia Zhi has actively engaged with investors through platforms like Ant Wealth, where he has a following of 796,000 and has reported a one-year return of 32.38% on his investments [4]. Group 3: Industry Trends - The fund management industry is experiencing a significant increase in the number of fund managers, with the total number reaching 4,146 as of March 5, 2026 [7]. - The transition from sell-side to buy-side roles is becoming more common, with many new fund managers having previously worked as researchers, often within a shorter timeframe [8]. - Despite the growth in numbers, there are concerns regarding the stability and experience of the fund manager workforce, with an average tenure of only 5.15 years [10].

Core Insights - The public fund market will see the launch of 29 new funds in the first week of February 2026, with equity products remaining the dominant category [1] Fund Distribution - Among the 29 new funds, there are 11 equity funds, 7 mixed funds, 6 FOFs (Fund of Funds), and 5 bond funds, with an average subscription period of 12 days [3] - Active equity products include 8 funds with an average subscription period of approximately 13 days, including 2 pharmaceutical-themed products: Shangyin Medical Selection and Guangfa Medical Innovation Selection, the latter having a fundraising cap of 8 billion units and a subscription period of 3 days [4] - Passive index products feature themes such as biotechnology, non-ferrous metals, and batteries, with an average subscription period of 10 days. Three products have a fundraising cap of 8 billion units: E Fund CSI Battery Theme ETF, Bosera CSI Industrial Non-Ferrous Metals Theme ETF, and E Fund CSI All-Share Dividend Quality ETF [4] - The 6 FOFs have an average subscription period of about 11 days, all with a 3-month holding period, and three have a fundraising cap of 8 billion units: Guangfa Yuefeng Multi-Asset Stable Three-Month Holding, Guotou Ruijin Multi-Asset Stable Three-Month Holding, and Tianhong Yingxiang Multi-Asset Leading Three-Month Holding [4] - The 5 bond funds have an average subscription period of approximately 18 days, with Luobomai Tianhang and Nongyin Ruiheng setting a fundraising cap of 6 billion units [4]

Core Insights - The biotechnology industry is rapidly developing and is a key direction for global technological revolution and industrial upgrading, with innovative drugs being a core engine of the industry [1] - The Hong Kong stock market is becoming an important platform for financing and value discovery for biotechnology companies, driven by favorable policies, active capital, and technological breakthroughs [1] - China is transitioning from "broad innovation" to "differentiated innovation and international development," with a significant increase in the approval and market entry of innovative drugs [2] Industry Overview - The biotechnology sector is a strategic emerging industry based on life sciences, encompassing innovative drugs, gene technology, and cell therapy, supported by a threefold driving force of policy benefits, capital support, and technological advancements [1] - The demand for treatment of diseases such as tumors and cardiovascular conditions is expected to grow due to an aging population and increased healthcare spending, providing substantial growth opportunities for the industry [2] Market Trends - The global mergers and acquisitions (M&A) in the pharmaceutical and biotechnology sectors are expected to reach a historical high by 2026, with significant activity in the Hong Kong stock market [1] - In 2025, China is projected to have 76 innovative drugs approved for market entry, with over 80% being domestic innovations, and a record-breaking total of over $130 billion in licensing-out transactions [2] Investment Opportunities - The Hang Seng Biotechnology Index (HSBIO.HI) highlights the investment value of high-purity and scarce biotechnology companies, with a significant focus on cutting-edge technologies [3] - The HSBIO index has shown a remarkable performance, with an increase of 82.2% over the past year, outperforming similar indices in the healthcare sector [3] - The launch of the Guangfa Hang Seng Biotechnology ETF aims to facilitate efficient investment in core biotechnology assets in Hong Kong, with advantages such as T+0 trading and low fees [3][4]